12 September 2019

Bristol Haematology and Oncology Centre accredited for excellence in myeloma healthcare provision

The Bristol Haematology and Oncology Centre (BHOC) has recently received a Clinical Service Excellence Programme (CSEP) Accreditation from the charity Myeloma UK.

The Myeloma UK CSEP Accreditation recognises the hospital's commitment to providing superior treatment to myeloma patients, and helping to make improvements in the wider healthcare community.

Myeloma is the third most common form of blood cancer, and whilst treatable is not yet curable.

Jenny Bird, haematology consultant at the Bristol Haematology and Oncology Centre, explains what the team has done to achieve this award:

"We aim to provide our patients with an outstanding experience from the minute they set foot in the BHOC, which can be a daunting experience for anyone.

"We provide them with clear information, advice and support throughout their journey with us, and give the best and most current treatments and access to a broad range of clinical trials.

"Working as part of a multidisciplinary team, we have good relationships with all our colleagues in radiology, pharmacy, pathology and radiotherapy, as well as having a highly skilled and responsive palliative care team.

"It's with thanks to all members of the myeloma team that this is possible, and I'd also like to thank our patients and their families, who participate in their care, tell us what they want and are so courageous in the way they live with myeloma."

Suzanne Renwick, Healthcare Professional Projects Manager, Myeloma UK, said:

"Being presented with the Myeloma UK CSEP Accreditation is a considerable achievement and shows that the Bristol Haematology and Oncology Centre is dedicated to providing excellent treatment and care.

"The Myeloma UK CSEP accreditation demonstrates the gold standard of myeloma care."

BACK TO NEWS